CONSULTING AGREEMENT

This CONSULTING AGREEMENT (this “Agreement”), is made this 1st day of June, 2026 by Atea Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Bruno Lucidi (the “Consultant”).

INTRODUCTION

The Company and the Consultant desire to establish the terms and conditions under which the Consultant will provide services to the Company. In consideration of the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties hereto, the parties agree as follows:

1.

Services.

1.1

The Consultant agrees to perform such consulting, advisory and related services to and for the Company as may be reasonably requested from time to time by the Company, including without limitation with respect to the commercialization, pricing and reimbursement of the Company’s products outside of the United States.

1.2

…

TERMINATION AND RELEASE AGREEMENT

This Termination and Release Agreement (this "Agreement"), dated as of June 22, 2026, is made by and between Honeywell International Inc., a corporation organized under the Laws of the State of Delaware ("Honeywell"), and Resideo Technologies, Inc., a corporation organized under the Laws of the State of Delaware ("Resideo" and, together with Honeywell, the "Parties" and each a "Party"). Capitalized terms used but not defined herein shall have meanings ascribed to such terms in the TMA (as defined below), and if not defined in the TMA, as defined in the Separation Agreement (as defined in the TMA).

WHEREAS, Honeywell and Resideo are parties to that certain Tax Matters Agreement, dated as of October 19, 2018 (as may be amended or modified from time to time, the ("TMA"), which was entered into as part of the spin-off of Resideo from Honeywell; and

…

June 2, 2026

Tom Surran

Dear Tom:

I am pleased to extend this offer to become President and Chief Executive Officer ("CEO") of Resideo Technologies, Inc. (“Resideo” or the “Company”), effective as of, and contingent upon, the anticipated spin-off of ADI Global Distribution Inc. (the "Spin-off"). The date of the Spin-off and your consequent appointment as CEO is hereinafter referred to as the "Effective Date". As of the Effective Date, you will also be appointed to the Resideo Board of Directors (the "Board"), consistent with the Company's governing documents.

For the sake of clarity, should the Spin-off not occur as anticipated, this offer automatically becomes null and void.

As of the Effective Date, your employment will be subject to the terms and conditions of this offer letter, and you will be entitled to the following compensation and benefits package, which has been approved by the Compensation and Human Capital Management Committee of the Board (the “CHCM Committee”).

Page 1 of Page 5

---

COMPENSATION

Base Salary

…

EMPLOYMENT AGREEMENT

This EMPLOYMENT AGREEMENT (this “Agreement”) is made as of the latest date set forth on the signature page below, by and between RED ROBIN GOURMET BURGERS, INC., a Delaware corporation (the “Company”), and JOHN MCLAUGHLIN (“Executive”).

RECITAL

WHEREAS, the parties desire to enter into this Agreement setting forth the terms and conditions for the employment relationship between Executive and the Company.

NOW, THEREFORE, in consideration of the promises and mutual covenants and agreements herein contained and intending to be legally bound hereby, the Company and Executive hereby agree as follows:

AGREEMENT

1.Employment Period.

…

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

PROMISSORY NOTE

** **

---

Principal Amount: $190,000	Dated as of May __, 2026

** **

…

AMENDED AND RESTATED EMPLOYMENTAGREEMENT

ThisAMENDEDANDRESTATEDEMPLOYMENTAGREEMENT(this“Agreement”) is made and entered into as of April 14, 2026, by and between Kailera Therapeutics, Inc., a Delawarecorporation(the“Company”),andPaulBurgess(the“Executive”),andwillbeeffective as of the Effective Date (as defined below). Certain capitalized terms used, but not otherwise defined, in this Agreement are defined in Section 6 hereof.

WHEREAS,theCompanyandExecutivepreviouslyenteredintothatcertainEmployment Agreement, dated as of September 14, 2024 (the “Prior Agreement”);

WHEREAS,effectiveonthedateuponwhichtheRegistrationStatementonFormS-1filed with the Securities and Exchange Commission relating to the registered underwritten public offeringoftheCompany’scommonstockbecomeseffective(the“EffectiveDate”),theCompany desires to continue to benefit from the services of the Executive, and the Executive desires to continue to render such services, on the terms and conditions set forth in this Agreement; and

…

AMENDED AND RESTATED

EMPLOYMENTAGREEMENT

ThisAMENDEDANDRESTATEDEMPLOYMENTAGREEMENT(this“Agreement”) is made and entered into as of April 14, 2026, by and between Kailera Therapeutics, Inc., a Delaware corporation (the “Company”), and Jamie Coleman (the “Executive”), and will be effective as of the Effective Date (as defined below). Certain capitalized terms used, but not otherwise defined, in this Agreement are defined in Section 6 hereof.

WHEREAS,theCompanyandExecutivepreviouslyenteredintothatcertainEmployment Agreement, dated as of January 3, 2025 (the “Prior Agreement”);

WHEREAS,effectiveonthedateuponwhichtheRegistrationStatementonFormS-1filed with the Securities and Exchange Commission relating to the registered underwritten public offeringoftheCompany’scommonstockbecomeseffective(the“EffectiveDate”),theCompany desires to continue to benefit from the services of the Executive, and the Executive desires to continue to render such services, on the terms and conditions set forth in this Agreement; and

…

SECONDAMENDEDANDRESTATED

EMPLOYMENT AGREEMENT

ThisSECONDAMENDEDANDRESTATEDEMPLOYMENTAGREEMENT(this “Agreement”)ismadeandenteredintoasofApril15,2026,byandbetweenKaileraTherapeutics, Inc.,aDelawarecorporation(the“Company”),andRonaldRenaud(the“Executive”),andwillbe effective as of the Effective Date (as defined below). Certain capitalized terms used, but not otherwise defined, in this Agreement are defined in Section 6 hereof.

WHEREAS, the Company and Executive previously entered into that certain Amended and Restated Employment Agreement, dated as of December 6, 2024 (the “Prior Agreement”);

WHEREAS,effectiveonthedateuponwhichtheRegistrationStatementonFormS-1filed with the Securities and Exchange Commission relating to the registered underwritten public offeringoftheCompany’scommonstockbecomeseffective(the“EffectiveDate”),theCompany desires to continue to benefit from the services of the Executive, and the Executive desires to continue to render such services, on the terms and conditions set forth in this Agreement; and

…

July 4, 2026

Michael Vyvoda

Re:    Employment Terms

Dear Michael:

Enovix Corporation (the “Company”) is pleased to offer you the position of Chief Operating Officer reporting to the Chief Executive Officer (the “CEO”) subject to the terms and conditions provided herein effective as of the date you commence employment hereunder, which is expected to be on or around July 29, 2026 (the “Start Date”). Your base salary will be $440,000 (the “Base Salary”) which will be subject to adjustment pursuant to the Company’s employee compensation policies as may be in effect from time to time and periodic reviews, less payroll deductions and withholdings. You will be eligible for an annual discretionary bonus and your annual bonus target will be 60% of your Base Salary. The bonus payout will be based on achievement of specific performance goals and will be subject to the terms and conditions of the Enovix Bonus Plan specification, your continued employment through the payment date and approval by the Board of Directors (the “Board”).

…

SUBLEASE AGREEMENT

This Sublease Agreement (“Sublease”) is dated as of June 15, 2026 (the “Effective Date”), by and between ANAPTYSBIO, INC., a Delaware corporation (“Sublandlord”), and FIRST TRACKS BIOTHERAPEUTICS, INC., a Delaware corporation, (“Subtenant”).

RECITALS

A.Sublandlord currently leases certain premises from WATERIDGE PROPERTY OWNER, LP, a Delaware limited partnership (the “Master Landlord”), pursuant to the terms and conditions of that certain Lease dated May 4, 2020, as amended by that certain First Amendment to Lease Agreement, dated April 5, 2021 (as so amended, the “Master Lease”). Pursuant to the Master Lease, Sublandlord currently leases from Master Landlord approximately 45,057 rentable square feet of space (the “Premises”) located in that certain building located in 10770 Wateridge Circle, San Diego, CA 92121 (the “Building”), as more specifically described in the Lease. Sublandlord represents that a true, correct and complete copy of the Master Lease is attached hereto as Exhibit A. All terms capitalized but undefined herein shall have the meanings ascribed

…

INDEMNITY AGREEMENT

This Indemnity Agreement (the “Agreement”), dated as of _____________, 2026 is made by and between First Tracks Biotherapeutics, Inc., a Delaware corporation (the “Company”), and [Insert Name], a director, officer or key employee of the Company or one of the Company’s Subsidiaries or Affiliates (as those terms are defined below) or other service provider who satisfies the definition of Indemnifiable Person set forth below (“Indemnitee”).

RECITALS

A. The Company is aware that competent and experienced persons are increasingly reluctant to serve as representatives of corporations unless they are protected by comprehensive liability insurance and indemnification, due to increased exposure to litigation costs and risks resulting from their service to such corporations, and due to the fact that the exposure frequently bears no relationship to the compensation of such representatives;

…

-1- AMENDMENT NO. 2 TO THE LIMITED LIABILITY COMPANY AGREEMENT OF AT UMBRELLA LLC July 22, 2026 This Amendment No. 2 (the “Amendment”) to the Limited Liability Company Agreement of AT Umbrella LLC, a Delaware limited liability company (the “Company”), dated as of December 16, 2025 and as amended (the “Agreement”), is entered into by the undersigned Members of the Company effective as of the date first written above (the “Effective Date”). All capitalized terms used but not defined herein have the respective meanings ascribed to such terms in the Agreement. RECITALS WHEREAS, pursuant to Section 13.09(a) of the Agreement, the Agreement may be amended with the written consent of Members constituting a majority in interest of all Members, which majority must include Aggregator (the “Requisite Majority”); and WHEREAS, the undersigned Members, constituting the Requisite Majority, desire to amend the Agreement as provided herein. NOW, THEREFORE, BE IT RESOLVED, that the Agreement is hereby amended as follows: 1. Amendment to Section 1.01(a). The defined term “Permitted Exchange” in Section

…